Trial Profile
BoRtezomib-based Optimized therapy Aiming Disease control in Japan 2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms BROAD-J 2 study
- 09 Oct 2018 Status changed from recruiting to completed.
- 03 Sep 2013 New trial record